Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative gleason sum of 8 to 10

Cancer

Volumn 107, Issue 6, 2006, Pages 1265-1272

  Bastian, Patrick J ^a   Gonzalgo, Mark L ^a   Aronson, William J ^b,c   Terris, Martha K ^d,e   Kane, Christopher J ^f,g   Amling, Christopher L ^h,i   Presti Jr , Joseph C ^j,k   Mangold, Leslie A ^a   Humphreys, Elizabeth ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a   Freedland, Stephen J ^a,l,m,n  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Alabama   (United States)

ⁱ NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^l DURHAM VA MEDICAL CENTER   (United States)

^m DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Gleason score 8 to 10; High risk; Prostate cancer; Radical prostatectomy; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE INTERVAL; GLEASON SCORE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; BIOPSY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33749003186     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22116     Document Type: Review

References (32)

1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555-565.
2. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
3. Tefilli MV, Gheiler EL, Tiguert R, et al. Role of radical prostatectomy in patients with prostate cancer of high Gleason score. Prostate. 1999;39:60-66.
4. Manoharan M, Bird VG, Kim SS, Civantos F, Soloway MS. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥8. BJU Int. 2003;92:539-544.
5. Bianco FJ Jr., Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta" ). Urology. 2005;66(5 Suppl):83-94.
6. Saranchuk JW, Kattan MW, Elkin E, Touijer AK, Scardino PT, Eastham JA. Achieving optimal outcomes after radical prostatectomy. J Clin Oncol. 2005;23:4146-4151.
7. Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol. 2004;172(5 Pt 1):1835-1839.
8. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002;167:117-122.
9. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;71:3582-3593.
10. Freedland SJ, Amling CL, Dorey F, et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002;60:670-674.
11. Khan MA, Partin AW. Management of high-risk populations with locally advanced prostate cancer. Oncologist. 2003;8:259-269.
12. Gerber GS, Thisted RA, Chodak GW, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol. 1997;32:385-390.
13. Zincke H, Fleming TR, Furlow WL, Myers RP, Utz DC. Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate. Cancer. 1981;47:1901-1910.
14. Partin AW, Lee BR, Carmichael M, Walsh PC, Epstein JI. Radical prostatectomy for high grade disease: a reevaluation 1994. J Urol. 1994;151:1583-1586.
15. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-2101.
16. Mian BM, Troncoso P, Okihara K, et al, Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol. 2002;167:1675-1680.
17. Oefelein MG, Smith ND, Grayhack JT, Schaeffer AJ, McVary KT. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol. 1997;158:1460-1465.
18. Sciarra A, Gentile V, Voria G, et al. Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10. Urol Int. 2003;70:186-194.
19. Rioux-Leclercq NC, Chan DY, Epstein JI. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. Urology. 2002;60:666-669.
20. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003;169:157-163.
21. Kane CJ, Presti JC Jr., Amling CL, Aronson WJ, Terris MK, Freedland SJ. Changing nature of high-risk patients undergoing radical prostatectomy. J Urol. In press.
22. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994;152(5 Pt 2):1821-1825.
23. Freedland SJ, Mangold LA, Walsh PC, Partin AW. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol. 2005;174(4 Pt 1):1276-1281; Discussion 1281; Author Reply 1281.
24. Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ. Preoperative PSA and progression-free survival after radical prostatectomy for Stage Tie disease. Urology. 2005;66:156-160.
25. Freedland SJ, Aronson WJ, Terris MK, et al. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol. 2003;169:2136-2141.
26. D'Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol. 2004;22:3726-3732.
27. Grossfeld GD, Chang JJ, Broering JM, et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol. 2001;165:851-856.
28. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
29. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
30. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res. 2005;11:4037-4043.
31. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499.
32. Bachor R, Kocher F, Gropengiesser F, Reske SN, Hautmann RE. [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results] (in German). Urologe A. 1995;34:138-142.